Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA issues safety update guidance addendum

Executive Summary

Summary bridging reports should be used to combine information presented in multiple periodic safety update reports, FDA says in 1addendum to the May 1997 guidance "E2C Clinical Safety Data Management: Periodic Safety Update Reports For Marketed Drugs." In addition, sponsors should use an addendum report to update a completed PSUR if the agency asks for safety data outside of the usual reporting cycle. The guidance was discussed during a March 2002 meeting (2"The Pink Sheet" March 18, 2002, p. 42)...

You may also be interested in...



Good Vigilance Practice Guideline Sought For More Consistent PSUR Reviews

The development of good vigilance practices will be the focus of both European Union and International Conference on Harmonization working groups

Illumina Will Pay $8Bn To Buy Back Cancer Screening Start-Up Grail

Illumina announced today it will buy back Grail to allow faster adoption of its liquid biopsy test.

Roche’s Ipatasertib Promising In Prostate, But Disappointing In Breast Cancer

Roche is hoping the investigational oral drug can help it expand its presence in breast cancer and break into the prostate cancer market – but the signals are decidedly mixed.

UsernamePublicRestriction

Register

LL016789

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel